Prognostic nutritional index as a predictor of prognosis in patients with diffuse large B cell lymphoma

被引:23
作者
Perisa, Vlatka [1 ,2 ]
Zibar, Lada [2 ,3 ]
Knezovic, Ana [4 ]
Perisa, Igor [5 ]
Sincic-Petricevic, Jasminka [1 ]
Aurer, Igor [6 ,7 ]
机构
[1] Osijek Univ Hosp, Clin Internal Med, Dept Hematol, Josipa Huttlera 4, HR-31000 Osijek, Croatia
[2] Univ Osijek, Fac Med, Dept Pathophysiol, Josipa Huttlera 4, HR-31000 Osijek, Croatia
[3] Osijek Univ, Clin Internal Med, Dept Nephrol, Josipa Huttlera 4, HR-31000 Osijek, Croatia
[4] Community Hlth Ctr Dakovo, P Preradovica 2, HR-31400 Dakovo, Croatia
[5] Community Hlth Ctr Vinkovci, Ul Kralja Zvonimira 53, HR-32100 Vinkovci, Croatia
[6] Univ Zagreb, Univ Hosp Ctr Zagreb, Dept Internal Med, Div Hematol, Kispaticeva 12, HR-10000 Zagreb, Croatia
[7] Univ Zagreb, Sch Med, Kispaticeva 12, HR-10000 Zagreb, Croatia
关键词
Lymphoma; large B-cell; diffuse; Prognostic nutritional index; Prognostic marker; Prognosis; ABSOLUTE LYMPHOCYTE; SURVIVAL; EXPRESSION; MARKER; INFLAMMATION; COUNTS; CANCER;
D O I
10.1007/s00508-016-1077-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The prognostic nutritional index (PNI), an indicator of nutritional status and systemic inflammation, is associated with short-term and long-term outcomes of various malignancies. The prognostic value of PNI in diffuse large B cell lymphoma (DLBCL) remains unknown. The aim of the present study was to determine the prognostic value of baseline PNI in DLBCL patients. We retrospectively analyzed data from 103 DLBCL patients treated with RaEuroCHOP or RaEuroCHOP-like regimens. We evaluated the significance of PNI as a predictor of response to treatment, overall survival (OS) and event-free survival (EFS). Patients with a PNI ae<currency> 44.55, where the cut-off was calculated by receiver operating characteristics (Youden index) and the same was obtained for response to treatment with 76.2 % sensitivity and a specificity of 85.4 %, for OS with 72.4 % sensitivity and a specificity of 90.5 % and for EFS with 65.6 % sensitivity and a specificity of 90.1 %, had significantly worse 5aEuroyear OS (18.3 % vs 86.4 %, P < 0.001, log rank test) and 5aEuroyear EFS (15.1 % vs 82.3 %, P < 0.001, log rank test). Regression analysis showed that PNI >= 44.55 was an independent prognostic factor for response to treatment with an odds ratio (OR) of 4.88 for treatment failure, 95 % confidence interval (CI) 1.077-22.105, OS hazard ratio (HR) 4.24, 95 % CI 1.451-12.392 and EFS HR 4.007, 95 % CI 1.48-10.852. Lower PNI levels were found in patients with advanced Ann Arbor clinical stage (46.6 +/- 7.77 vs. 52.7 +/- 5.43) and in those with poor response to therapy (40.58 +/- 7.26 vs. 50.67 +/- 6.26). The PNI is a simple and useful marker to predict long-term survival outcome in DLBCL patients. Low PNI predicted poor outcome. A limitation of the study is its retrospective design in which the prognostic value was tested in the derivation cohort only. Notwithstanding, this is the first study suggesting that PNI is an important prognostic factor in DLBCL.
引用
收藏
页码:411 / 419
页数:9
相关论文
共 32 条
  • [1] [Anonymous], NENGLJMED
  • [2] [Anonymous], MINERVA MED
  • [3] The Prognostic Impact of Absolute Lymphocyte and Monocyte Counts at Diagnosis of Diffuse Large B-Cell Lymphoma in the Rituximab Era
    Aoki, Kazunari
    Tabata, Sumie
    Yonetani, Noboru
    Matsushita, Akiko
    Ishikawa, Takayuki
    [J]. ACTA HAEMATOLOGICA, 2013, 130 (04) : 242 - 246
  • [4] Aviles A, 1995, Arch Med Res, V26, P31
  • [5] Evaluation of BCL-6, CD10, CD 138 and MUM-1 Expression in Diffuse Large B-Cell Lymphoma patients: CD138 is a Marker of Poor Prognosis
    Bodoori, Khaldon
    Matalka, Ismail
    Hayajnehi, Rami
    Haddad, Yazan
    Gharaibeh, Waleed
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (07) : 3037 - 3046
  • [6] PROGNOSTIC NUTRITIONAL INDEX IN GASTROINTESTINAL SURGERY
    BUZBY, GP
    MULLEN, JL
    MATTHEWS, DC
    HOBBS, CL
    ROSATO, EF
    [J]. AMERICAN JOURNAL OF SURGERY, 1980, 139 (01) : 160 - 167
  • [7] The prognostic nutritional index predicts survival for patients with extranodal natural killer/T cell lymphoma, nasal type
    Chen, Kai-Lin
    Liu, Yan-Hui
    Li, Wen-Yu
    Chen, Jie
    Gu, Yang-Kui
    Geng, Qi-Rong
    Jiang, Wen-Qi
    Huang, Hui-Qiang
    Lin, Tong-Yu
    Xia, Zhong-Jun
    Cai, Qing-Qing
    [J]. ANNALS OF HEMATOLOGY, 2015, 94 (08) : 1389 - 1400
  • [8] Revised response criteria for malignant lymphoma
    Cheson, Bruce D.
    Pfistner, Beate
    Juweid, Malik E.
    Gascoyne, Randy D.
    Specht, Lena
    Horning, Sandra J.
    Coiffier, Bertrand
    Fisher, Richard I.
    Hagenbeek, Anton
    Zucca, Emanuele
    Rosen, Steven T.
    Stroobants, Sigrid
    Lister, T. Andrew
    Hoppe, Richard T.
    Dreyling, Martin
    Tobinai, Kensei
    Vose, Julie M.
    Connors, Joseph M.
    Federico, Massimo
    Diehl, Volker
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) : 579 - 586
  • [9] Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era
    Dalia, Samir
    Chavez, Julio
    Little, Bryan
    Bello, Celeste
    Fisher, Kate
    Lee, Ji-Hyun
    Chervenick, Paul
    Sokol, Lubomir
    Sotomayor, Eduardo
    Shah, Bijal
    [J]. ANNALS OF HEMATOLOGY, 2014, 93 (08) : 1305 - 1312
  • [10] Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature
    Gupta, Digant
    Lis, Christopher G.
    [J]. NUTRITION JOURNAL, 2010, 9